|
2008 Conference Publication Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) populationKeane, Colm G., Mollee, Peter, Marlton, Paula and Gill, Devinder (2008). Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.4014.4014 |
|
2008 Conference Publication Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitroGill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.3157.3157 |
|
2008 Conference Publication Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitroGill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th Annual Meeting of the American- Society-of-Hematology, San Francisco, CA, United States, 6 - 9 December 2008. Washington, DC, United States: American Society of Hematology. |
|
2008 Conference Publication Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlationsTate, J.R., Bazeley, S., Sykes, S. and Mollee, P. (2008). Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations. 60th Annual Meeting of the American Association for Clinical Chemistry, Washington, DC, United States, 27-31 July 2008. Washington, DC, United States: American Association for Clinical Chemistry. |
|
2007 Conference Publication JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)Weston, Helen, Bird, Robert, Griffiths, Vanessa, Jones, Mark, Grimmett, Karen, Saal, Russell, Mills, Anthony K., Gill, Devinder, Marlton, Paula and Mollee, Peter (2007). JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th ASH Annual Meeting, Atlanta, GA United States, 8-11 December 2007. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v110.11.2551.2551 |
|
2007 Conference Publication Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patientsMollee, Peter, Hourigan, Matthew, Johnson, David, Jones, Mark, Isbel, Nikki, Hawley, Carmel, Marlton, Paula, Gandhi, Maher, Campbell, Scott and Gill, Devinder (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA USA, 8-11 December 2007. Washington, DC USA: American Society of Hematology. |
|
2007 Conference Publication JAK2V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)Weston, H, Bird, R, Griffiths, V, Jones, M, Grimmett, K, Saal, R, Mills, AK, Gill, D, Marlton, P and Mollee, P (2007). JAK2V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th Annual Meeting of the American-Society-of-Hematology, Atlanta Ga, Dec 08-11, 2007. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2007 Conference Publication Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2007 Conference Publication Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant PatientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Ghandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. American Transplant Congress 2007, USA, 5-9 May 2007. UK: Wiley-Blackwell Publising Ltd.. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2007 Conference Publication Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II studyTrappe, R., Choquet, S., Oertel, S., LeBlond, V., Ekman, T., Sender, M., Mollee, P, Reinke, P., Lehmkuhl, H., Hummel, M., Jonas, S., Neuhaus, R., Salles, G., Morschhauser, F., Jaccard, A., Anagnostopoulos, I., Raphael, M. and Riess, H. (2007). Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study. Annual American Transplant Congress, San Francisco, CA, United States, 5 - 9 May 2007. Malden, MA, United States: Wiley-Blackwell Publishing. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2006 Conference Publication Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patientsGill, Saar, Lane, Steven, Crawford, Julie, Mollee, Peter, Marlton, Paula, Cull, Gavin, Prince, Miles and Seymour, John Francis (2006). Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patients. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.v108.11.2441.2441 |
|
2006 Conference Publication Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).Lane, SW, Saal, R, Mollee, P, Grigg, A, Taylor, K, Seymour, JF, Kennedy, G, Williams, B, Jones, M, Grimmett, K, Griffiths, V, Gill, D, Hourigan, M and Marlton, P (2006). Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. |
|
2006 Conference Publication Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseasesTate, J.R., Mollee, P., Carter, A. and Gill, D. (2006). Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases. 58th Annual Meeting of the American Association of Clinical Chemistry, Chicago, IL, United States, 23-27 July 2006. Washington, DC, United States: American Association for Clinical Chemistry. |
|
2006 Conference Publication Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).Lane, SW, Saal, R, Negus, S, Mollee, P, Mather, M, Gill, D, Mills, AK, Bird, RJ, Hourigan, MJ, Jones, M and Marlton, P (2006). Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando Fl, Dec 09-12, 2006. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2005 Conference Publication Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)Lane, Steven W., Mollee, Peter N., Bird, Robert, Porceddu, Sandro and Gill, Devinder (2005). Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL). 47th ASH Annual Meeting, Atlanta, GA United States, 10-13 December 2005. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v106.11.4993.4993 |
|
2005 Conference Publication Falsely low serum free light chain concentration in patients with monoclonal light chain diseasesMollee, Peter, Tate, Jill, Dimeski, Goce and Gill, Devinder (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. 47th ASH Annual Meeting, Atlanta, GA United States, 10-13 December 2005. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v106.11.5077.5077 |
|
2005 Conference Publication Falsely low serum free light chain concentration in patients with monoclonal light chain diseasesMollee, Peter, Tate, Jill, Dimeski, Goce and Gill, Devinder (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. |
|
2005 Conference Publication Accelerated delivery of Rituximab is safe on an out-patient basis.Middleton, HJ, Mollee, P, Bird, R, Mills, AK, Marlton, P and Gill, D (2005). Accelerated delivery of Rituximab is safe on an out-patient basis.. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta Ga, Dec 10-13, 2005. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2005 Conference Publication Falsely low serum free light chain concentration in patients with monoclonal light chain diseasesTate, J.R., Mollee, P., Dimeski, G. and Gill, D. (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. Annual Meeting of the American Association Clinical Chemistry, Orlando, FL, United States, 24-28 July 2005. Washington, DC, United States: American Association for Clinical Chemistry. |
|
2005 Conference Publication Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.Lane, SW, Crawford, J, Kenealy, M, Cull, G, Seymour, JF, Prince, M, Marlton, P, Gill, D and Mollee, PN (2005). Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V106.11.4274.4274 |
